Capital Flow Monitor · Sponsors · CIK 1806540
Lycia Therapeutics, Inc.
400 EAST JAMIE COURT, SUITE 200, SOUTH SAN FRANCISCO, CA, 94080 · (650) 392-3357
Biotechnology · Corporation· inc. DELAWARE true
Fit score
—
Offering
$75.0M
Sold
$75.0M
% sold
100.0%
Investors
16
Min investment
$0
Exemption
506(b)
Filing history
| Filed | Form | Rule | Offering | Sold | % sold | Investors | |
|---|---|---|---|---|---|---|---|
| 2026-06-25 | D ·current | 506(b) | $75.0M | $75.0M | 100.0% | 16 | EDGAR ↗ |
Related persons
Executive officers, directors and promoters, as filed. Other raises are matched by exact name and show amount sold as last reported.
- William Rieflin — Director, South San Francisco, CA
- Clare Ozawa — Director, South San Francisco, CA
-
Ming Fang — Director, South San Francisco, CA
1 other raise
- Abcuro, Inc. $39.4M of $176.5M · 22.3%
-
Laurent Fischer — Director, South San Francisco, CA
1 other raise
- Mirum Pharmaceuticals, Inc. $68.5M of $68.5M · 100.0%
- Tim Anderson — Director, South San Francisco, CA
- Aetna Wun Trombley — Executive Officer / Director, South San Francisco, CA
- Amy Bachrodt — Executive Officer, South San Francisco, CA
Placement agents
- No sales compensation reported — direct raise.
Source: SEC EDGAR Form D. Self-reported by the issuer. Not investment advice.